Statin use and its effect on all-cause mortality of melanoma patients: A population-based Dutch cohort study

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1284-1293

  Livingstone, Elisabeth ^a   Hollestein, Loes M ^b   van Herk Sukel, Myrthe P P ^c   van de Poll Franse, Lonneke ^d,e   Joosse, Arjen ^b   Schilling, Bastian ^a   Nijsten, Tamar ^b   Schadendorf, Dirk ^a   de Vries, Esther ^b,e  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^d TILBURG UNIVERSITY   (Netherlands)

^e Eindhoven Cancer Registry   (Netherlands)

Author keywords

HMG CoA reductase inhibitor; Melanoma; Statin; Survival

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DEATH; DISEASE SPECIFIC SURVIVAL; DRUG USE; DUTCHMAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL RATE; CAUSE OF DEATH; COMORBIDITY; FACTUAL DATABASE; HEALTH SURVEY; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; NETHERLANDS; PATHOLOGY; REGISTER; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; CAUSE OF DEATH; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NETHERLANDS; POPULATION SURVEILLANCE; REGISTRIES; TUMOR BURDEN;

EID: 84991511001     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.285     Document Type: Article

References (51)

1. Miller, A. J., and M. C. Mihm, Jr. 2006. Melanoma. N. Engl. J. Med. 355:51-65.
2. Arnold, M., C. Holterhues, L. M. Hollestein, J. W. Coebergh, T. Nijsten, E. Pukkala, et al. 2013. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J. Eur. Acad. Dermatol. Venereol. [Epub ahead of print].
3. Flaherty, K. T., J. R. Infante, A. Daud, R. Gonzalez, R. F. Kefford, J. Sosman, et al. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367:1694-1703.
4. Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:122-133.
5. Schachter, M. 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19:117-125.
6. Boudreau, D. M., O. Yu, and J. Johnson. 2010. Statin use and cancer risk: a comprehensive review. Expert Opin. Drug Saf. 9:603-621.
7. Deberardinis, R. J., N. Sayed, D. Ditsworth, and C. B. Thompson. 2008. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18:54-61.
8. Fritz, G. 2009. Targeting the mevalonate pathway for improved anticancer therapy. Curr. Cancer Drug Targets 9:626-638.
9. Jakobisiak, M., and J. Golab. 2003. Potential antitumor effects of statins (review). Int. J. Oncol. 23:1055-1069.
10. Favero, G. M., M. F. Otuki, K. A. Oliveira, M. S. Bohatch, Jr., P. Borelli, F. E. Barros, et al. 2010. Simvastatin impairs murine melanoma growth. Lipids Health Dis. 9:142.
11. Glynn, S. A., D. O'Sullivan, A. J. Eustace, M. Clynes, and N. O'Donovan. 2008. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 8:9.
12. Minichsdorfer, C., and M. Hohenegger. 2009. Autocrine amplification loop in statin-induced apoptosis of human melanoma cells. Br. J. Pharmacol. 157:1278-1290.
13. Saito, A., N. Saito, W. Mol, H. Furukawa, A. Tsutsumida, A. Oyama, et al. 2008. Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 18:85-94.
14. Tilkin-Mariame, A. F., C. Cormary, N. Ferro, G. Sarrabayrouse, I. Lajoie-Mazenc, J. C. Faye, et al. 2005. Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression. FASEB J. 19:1513-1515.
15. Kidera, Y., M. Tsubaki, Y. Yamazoe, K. Shoji, H. Nakamura, M. Ogaki, et al. 2010. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J. Exp. Clin. Cancer Res. 29:127.
16. Jani, J. P., S. Specht, N. Stemmler, K. Blanock, S. V. Singh, V. Gupta, et al. 1993. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13:314-324.
17. Pich, C., I. Teiti, P. Rochaix, B. Mariame, B. Couderc, G. Favre, et al. 2013. Statins reduce melanoma development and metastasis through MICA overexpression. Front. Immunol. 4:62.
18. Hall, A., and C. D. Nobes. 2000. Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355:965-970.
19. Collisson, E. A., C. Kleer, M. Wu, A. De, S. S. Gambhir, S. D. Merajver, et al. 2003. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther. 2:941-948.
20. Freeman, S. R., A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, et al. 2006. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J. Natl. Cancer Inst. 98:1538-1546.
21. Bonovas, S., G. Nikolopoulos, K. Filioussi, E. Peponi, P. Bagos, and N. M. Sitaras. 2010. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur. J. Epidemiol. 25:29-35.
22. Dellavalle, R., A. Drake, M. Graber, L. Heilig, E. Hester, K. Johnson, et al. 2005. Statins and fibrates for preventing melanoma. Cochrane Database Syst. Rev. 4:CD003697.
23. Koomen, E. R., A. Joosse, R. M. Herings, M. K. Casparie, W. Bergman, T. Nijsten, et al. 2007. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur. J. Cancer 43:2580-2589.
24. Jagtap, D., C. A. Rosenberg, L. W. Martin, M. Pettinger, J. Khandekar, D. Lane, et al. 2012. Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. Cancer 118:5124-5131.
25. Ahern, T. P., L. Pedersen, M. Tarp, D. P. Cronin-Fenton, J. P. Garne, R. A. Silliman, et al. 2011. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J. Natl. Cancer Inst. 103:1461-1468.
26. Kwan, M. L., L. A. Habel, E. D. Flick, C. P. Quesenberry, and B. Caan. 2008. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res. Treat. 109:573-579.
27. Geybels, M. S., J. L. Wright, S. K. Holt, S. Kolb, Z. Feng, and J. L. Stanford. 2013. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate 73:1214-1222.
28. van Herk-Sukel, M. P., L. V. van de Poll-Franse, V. E. Lemmens, G. Vreugdenhil, J. F. Pruijt, J. W. Coebergh, et al. 2010. New opportunities for drug outcomes research in cancer patients: the linkage of the eindhoven cancer registry and the PHARMO record linkage system. Eur. J. Cancer 46:395-404.
29. Schouten, L. J., P. Hoppener, P. A. van den Brandt, J. A. Knottnerus, and J. J. Jager. 1993. Completeness of cancer registration in Limburg, The Netherlands. Int. J. Epidemiol. 22:369-376.
30. Herings, R. M., A. Bakker, B. H. Stricker, and G. Nap. 1992. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J. Epidemiol. Community Health 46:136-140.
31. Lau, H. S., A. de Boer, K. S. Beuning, and A. Porsius. 1997. Validation of pharmacy records in drug exposure assessment. J. Clin. Epidemiol. 50:619-625.
32. Buurma, H., M. L. Bouvy, P. A. De Smet, A. Floor-Schreudering, H. G. Leufkens, and A. C. Egberts. 2008. Prevalence and determinants of pharmacy shopping behaviour. J. Clin. Pharm. Ther. 33:17-23.
33. WHO. 2009. Definition and general considerations. In WHO Collaborating Centre for Drug Statistics Methodology, ed. Methodology. WHO, Oslo. Available at http://www.whocc.no/ddd/definition_and_general_considera/ (accessed 4 November 2012).
34. de Vries, E., S. Houterman, M. L. Janssen-Heijnen, T. Nijsten, S. A. van de Schans, A. M. Eggermont, et al. 2007. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann. Oncol. 18:1110-1116.
35. Hakulinen, T., and K. H. Abeywickrama. 1985. A computer program package for relative survival analysis. Comput. Programs Biomed. 19:197-207.
36. Suissa, S. 2008. Immortal time bias in pharmaco-epidemiology. Am. J. Epidemiol. 167:492-499.
37. Francis, S. O., M. J. Mahlberg, K. R. Johnson, M. E. Ming, and R. P. Dellavalle. 2006. Melanoma chemoprevention. J. Am. Acad. Dermatol. 55:849-861.
38. Demierre, M. F. 2005. Consideration of statins for chemoprevention of cutaneous melanoma. J. Drugs Dermatol. 4:125-128.
39. Collisson, E. A., D. C. Carranza, I. Y. Chen, and M. S. Kolodney. 2002. Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J. Invest Dermatol. 119:1172-1176.
40. Shellman, Y. G., D. Ribble, L. Miller, J. Gendall, K. Vanbuskirk, D. Kelly, et al. 2005. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 15:83-89.
41. Sarrabayrouse, G., C. Pich, R. Moriez, V. Armand-Labit, P. Rochaix, G. Favre, et al. 2010. Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells. PLoS One 5:e9043.
42. Kwak, B., F. Mulhaupt, S. Myit, and F. Mach. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:1399-1402.
43. Nielsen, S. F., B. G. Nordestgaard, and S. E. Bojesen. 2012. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367:1792-1802.
44. Cook, M. B., K. A. McGlynn, S. S. Devesa, N. D. Freedman, and W. F. Anderson. 2011. Sex disparities in cancer mortality and survival. Cancer Epidemiol. Biomarkers Prev. 20:1629-1637.
45. Joosse, A., S. Collette, S. Suciu, T. Nijsten, P. M. Patel, U. Keilholz, et al. 2013. Sex Is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five european organisation for research and treatment of cancer randomized controlled trials. J. Clin. Oncol. 31:2337-2346.
46. Joosse, A., S. Collette, S. Suciu, T. Nijsten, F. Lejeune, U. R. Kleeberg, et al. 2012. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and treatment of cancer phase III trials. J. Clin. Oncol. 30:2240-2247.
47. Krauthammer, M., Y. Kong, B. H. Ha, P. Evans, A. Bacchiocchi, J. P. McCusker, et al. 2012. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44:1006-1014.
48. Zbytek, B., J. A. Carlson, J. Granese, J. Ross, M. C. Mihm, Jr., and A. Slominski. 2008. Current concepts of metastasis in melanoma. Expert Rev. Dermatol. 3:569-585.
49. Bouman, A., M. J. Heineman, and M. M. Faas. 2005. Sex hormones and the immune response in humans. Hum. Reprod. Update 11:411-423.
50. Campbell, M. J., L. J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, E. Borman, et al. 2006. Breast cancer growth prevention by statins. Cancer Res. 66:8707-8714.
51. Katz, M. S. 2005. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat. Clin. Pract. Oncol. 2:82-89.